| 戴 丽,王小华,杨万春,杨庆斌,王凤玲,李 琪,孟祥云.贝伐珠单抗联合TP化疗方案对晚期非鳞癌非小细胞肺癌患者免疫功能、生活质量和血清肿瘤标志物的影响[J].,2021,(11):2174-2178 |
| 贝伐珠单抗联合TP化疗方案对晚期非鳞癌非小细胞肺癌患者免疫功能、生活质量和血清肿瘤标志物的影响 |
| Effect of Bevacizumab Combined with TP Chemotherapy on Immune Function, Quality of Life and Serum Tumor Markers in Patients with Advanced Non-small Cell Lung Cancer |
| 投稿时间：2021-01-07 修订日期：2021-01-30 |
| DOI：10.13241/j.cnki.pmb.2021.11.038 |
| 中文关键词: 贝伐珠单抗 TP化疗 晚期 非鳞癌非小细胞肺癌 免疫功能 生活质量 肿瘤标志物 |
| 英文关键词: Bevacizumab TP Chemotherapy Advanced NSCLC Immune function Quality of life Tumor markers |
| 基金项目:国家自然科学基金青年基金项目(82003849) |
|
| 摘要点击次数: 802 |
| 全文下载次数: 532 |
| 中文摘要: |
| 摘要 目的：探讨贝伐珠单抗联合紫杉醇加顺铂（TP）化疗方案对晚期非鳞癌非小细胞肺癌（NSNSCLC）患者免疫功能、生活质量和血清肿瘤标志物的影响。方法：选取2016年4月~2019年8月期间我院收治的晚期NSNSCLC患者80例。采用随机数字表法将患者分为对照组（n=40，TP化疗方案治疗）和研究组（n=40，对照组基础上联合贝伐珠单抗治疗），比较两组疗效、免疫功能、生活质量和血清肿瘤标志物，记录两组不良反应发生情况。结果：研究组治疗后的客观缓解率、疾病控制率高于对照组（P<0.05）。两组治疗后免疫球蛋白G（IgG）、免疫球蛋白M（IgM）、CD3+、CD4+、CD4+/CD8+、免疫球蛋白A（IgA）均下降，但研究组高于对照组（P<0.05）。两组治疗后社交/家庭状况、生理状况、情感状况、功能状况、肺癌附加的关注评分均升高，且研究组高于对照组（P<0.05）。两组治疗后癌胚抗原（CEA）、糖类抗原125（CA125）、细胞角蛋白19片段（CYFRA21-1）均下降，且研究组低于对照组（P<0.05）。两组不良反应发生率组间对比无明显差异（P>0.05）。结论：贝伐珠单抗联合TP化疗方案治疗晚期NSNSCLC患者，可有效阻止肿瘤进展，且能减小化疗对机体免疫功能影响，改善患者生活质量。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of bevacizumab combined with paclitaxel plus cisplatin (TP) chemotherapy on immune function, quality of life and serum tumor markers in patients with advanced non-small cell lung cancer (NSCLC). Methods: 80 patients with advanced NSCLC in our hospital from April 2016 to August 2019 were selected. The patients were randomly divided into the control group (n = 40，TP Chemotherapy) and the study group (n = 40, bevacizumab on the basis of the control group). The curative effect, immune function, quality of life and serum tumor markers of the two groups were compared, and the occurrence of adverse reactions in the two groups were recorded. Results: The objective remission rate and disease control rate of the study group after treatment were higher than those of the control group (P < 0.05). After treatment, immunoglobulin G (IgG), immunoglobulin M (IgM), CD3+, CD4+, CD4+/ CD8+, and immunoglobulin A (IGA) in the two groups decreased, but the study group was higher than the control group (P < 0.05). After treatment, the scores of social/family status, physiological status, emotional status, functional status, lung cancer status of lung cancer in the two groups increased, and the score in the study group was higher than that in the control group (P < 0.05). Carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and cytokeratin 19 fragment (CYFRA21-1) decreased in both groups after treatment, and the study group was lower than the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Bevacizumab combined with TP Chemotherapy in the treatment of patients with advanced NSCLC can effectively prevent tumor progression, reduce the impact of chemotherapy on immune function and improve the quality of life of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
